

8th YEAR 08-10 November 2024

InterContinental Dubai - Festival City United Arab Emirates



Morphoea in children, experience from a joint dermatology rheumatology clinic

Dr Charlotte Goodhead



Children's rheumatology

We provide specialist care for children with inflammatory diseases,











Learning Objectives

Clinical features

Scoring tools

Management

Case examples

Psychosocial impact

Morphoea, Morphea and Scleroderma....



'Scleroderma' was probably first used by Giovambattista Fantonetti in 1836 to describe a 30-year-old patient with skin swelling, pustules and progression to hard brown skin said to be 'as firm as leather'

- Scleroderma hard skin
- Morphoea form and structure

"In order to avoid unnecessary confusion on the part of both patients and doctors of other specialties, the authors postulate that localized scleroderma should be called morphea" (Dańczak-Pazdrowska 2021)

Classification



Tuffanelli and Winkelmann classification 1961

Morphea

Circumscribed, sclerotic plaques with an ivory-coloured centre and surrounding violaceous halo.

Linear scleroderma

Linear, band-like distribution

Frontal or frontoparietal linear scleroderma (en coup de sabre) is characterized by atrophy and a furrow or depression that extends below the level of the surrounding skin

Generalized morphea

Widespread skin involvement with multiple indurated plaques, hyperpigmentation and frequent muscle atrophy

(Asano 2018)



Peterson et al.classification 1995

Plaque morphea

Plaque morphea Guttate morphea Atrophoderma of Pasini and Pierini Keloid morphea (nodular morphea) (Lichen sclerosus et atrophicus) **Generalized morphea Bullous morphea** Linear morphea Linear morphea (linear scleroderma) Morphea en coup de sabre Progressive facial hemiatrophy **Deep morphea** Morphea profunda Subcutaneous morphea Eosinophilic fasciitis

Pansclerotic morphea of

Padua Consensus classification 2006

Circumscribed morphea

- (i) Superficial
- (ii) DeepLinear

Scleroderma

- (i) Trunk/limbs
- (ii) Head

Generalized Morphea Pansclerotic morphea Mixed morphea

Learning Objectives

Clinical features

Scoring tools

Management

Case examples

Psychosocial impact



Sclerosis of skin that can result in significant cosmetic and functional impairment

Often well-circumscribed Firm with loss of normal elasticity Often with a central pale or pigmented area surrounded by reddening at the margins

Two distinct phases;

PATIENT IMAGES

REMOVED

- 1. Inflammatory active stage with erythema and enlargement
- 2. Inactive, sclerotic, atrophic stage of damage

Can have a varied clinical presentation



PAEDIATRIC DERMATOLOGY

Linear morphoea follows Blaschko's lines

L. Weibel and J.I. Harper


Department of Paediatric Dermatology, Great Ormond Street Hospital for Children, London WC1N 3JH, U.K.


A retrospective chart review of 65 children with linear morphoea

- 53% had the en coup de sabre subtype,
- 41% linear morphoea on the trunk and /or limbs
- 6% a combination
- 85% were confined to one side of the body

Data indicated linear morphoea follows the lines of Blaschko


Authors hypothesize that in these patients' susceptible cells are present in a mosaic state, exposure to a trigger may result in the condition





(Weibel 2008)





PATIENT IMAGES REMOVED

Learning Objectives

Clinical features

Scoring tools

Management

Case examples

Psychosocial impact

MEDICAL DERMATOLOGY

Bitish Journal of Dermatology

Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change

N.M. Teske 🔞 and H.T. Jacobe 🔞

Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.

Linked Comment: Torok. Br J Dermatol 2020; 182:272-273.

Summary

Correspondence

Heidi Jacobe. E-mail: Heidi.jacobe@utsouthwestern.edu

Accepted for publication 1 May 2019

Funding sources

Funded by the James N. Gilliam, M.D., Chair in Dermatology at the University of Texas Southwestern Medical Center, created to enhance academic efforts in dermatology.

Conflicts of interest None to declare.

DOI 10.1111/bjd.18097

Background Validated scoring measures in morphoea can facilitate clinical trials. Objectives To ascertain the clinical significance of scores on the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) and identify the change in scores correlated with clinically meaningful change.

Methods A prospective study of 120 participants from the Morphea in Adults and Children (MAC) cohort was undertaken. Physician's subjective assessments of severity and of improvement were completed at each visit. Receiver operating characteristic analysis determined LoSCAT scores corresponding with mild, moderate and severe disease, and absolute and percentage changes in scores corresponding with improved or worsened disease activity or damage.

Realts Mild, moderate and severe activity corresponded with LoSCAT activity index (LoSAI) scores of 0-4, 5-12 and 13 and over, and with Physician's Global Assessment of activity (PGA-A) scores of 0-10, 11-30 and 31 and over. Mild, moderate and severe damage corresponded with LoSCAT damage index (LoSDI) scores of 0-10, 11-15 and 16 and over, and with PGA of damage (PGA-D) scores of 0-18, 19-30 and 31 and over. Improved activity was best indicated by LoSAI decrease of at least 2 points or $27\cdot5\%$, or PGA-A decrease of at least 6 points. Improved damage was best indicated by LoSDI score decrease of at least 2 points. Worsening activity was best indicated by LoSAI increase of at least 2 points or $19\cdot5\%$, or PGA-A increase of at least 4 points or $19\cdot5\%$, or PGA-A increase of at least 4 points or $19\cdot5\%$, or PGA-A increase of at least 5 $25\cdot5\%$.

Conclusions The LoSCAT can be used to classify patients with morphoea by disease severity, and identify clinically significant improvement in activity.

What's already known about this topic?

The Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) is a clinical tool
that separately quantifies disease activity and damage in morphoea, and prior studies have demonstrated validity and reliability.

What does this study add?

 The LoSCAT can be used to classify patients with morphoea by disease severity into mild moderate and severe groups, and to identify clinically claniformi improve



Localised Scleroderma Cutaneous Assessment Tool

LoSAI & LoSDI

Validated clinical measure Accounts for evolution of over time

LoSAI & PGA-A - Activity LoSDI & PGA-D - Damage

(Teske 2020)

		(Localized Sc	LoSAI leroderma Skin Ac	tivity Index)			oSDI ma Skin Damage Index)
	Scleroderma Cutaneous Assessment Tool	New/Enlarged (past month) 0 = none 3 = N / E	Erythema 0 = none 1 = pink 2 = red 3 = dark red Aiolaceous	Induration (skin swelling at EDGE) 0 = none 1 = mild 2 = moderate 3 = marked	Dermal atrophy 0 = none 1 = shiny 2 = visible vessels 3 = diff drop	Sub Q / Deep atrophy 0 = none 1 = flat 2 = concave 3 = marked	Dyspigmentation (hyper or hypo) 0 = none 1 = mild 2 = moderate 3 = marked	Skin Thickness (at CENTER) 0 = none 1 = mild 2 = moderate 3 = marked
	Scalp/Face							
	Neck							
	Chest							
	Abdomen							
	Upper Back							
	Lower Back							
	Arm							
	Forearm							
	Hand							
	Thigh							
	Leg							
	Foot							
	Arm							
	Forearm							
	Hand							
F	Thigh							
	Leg							
	Foot							
		LoSAI			LoSDI	_		
I	PGA-A (Ph	ysician Global	Assessment	of Disease <u>A</u>	ctivity)			
	(0=inactive)					(100	=markedly active)	
I		ysician Global	Assessment	of Disease D	amage)		,,	
	(0=no damag	je)				(100	=markedly damaged)	

LoSAI	– Activity index
0-4	Mild
5-12	Moderate
≥13	Severe
LoSDI	– Damage index
0-10	Mild
11-15	Moderate

≥16 Severe

Example scores over 2 years:

LoSAI = 15; LoSDI = 9; PGA-A =80; PGA-D =70 (Dec 22)
LoSAI = 0 LoSDI = 12; PGA-A =80; PGA-D =70 (June 23)
LoSAI = 0 LoSDI = 13; PGA-A =0; PGA-D =70 (Sept 23)
LoSAI = 0 LoSDI = 13; PGA-A =0; PGA-D =70 (Dec 23)
LoSAI = 2 LoSDI = 13; PGA-A =0; PGA-D =70 (Mar 24)
LoSAI = 2 LoSDI = 10; PGA-A =0; PGA-D =50 (Jun 24)
LoSAI = 0 LoSDI = 9; PGA-A = 0: PGA-D =50 (today)

Learning Objectives

Clinical features

Scoring tools

Management

Case examples

Psychosocial impact



ecommendation

Ann Rheum Dis: first published

2

Consensus-based recommendations for the management of juvenile localised scleroderma

Francesco Zulian, ^{• 1} Roberta Culpo, ¹ Francesca Sperotto, ¹ Jordi Anton, ² Tadej Avcin, ³ Eileen M Baildam, ⁴ Christina Boros, ⁵ Jeffrey Chaitow, ⁶ Tamàs Constantin, ⁷ Ozgur Kasapcopur, ⁸ Sheila Knupp Feitosa de Oliveira, ⁹ Clarissa A Pilkington, ¹⁰ Ricardo Russo, ¹¹ Natasa Toplak, ³ Annet van Royen, ¹² Claudia Saad Magalhães, ¹³ Sebastiaan J Vastert, ¹² Nico M Wulffraat, ¹² Ivan Foeldvari¹⁴

Handling editor Josef S Smolen

OPEN ACCESS

 Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/

ABSTRACT

In 2012, a European initiative called Single Hub an Access point for paediatric Rheumatology in Europ (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases.

Overarching principle

All children with suspected localised scleroderma should be referred to a specialised paediatric rheumatology centre.

(Zulian 2019)

- 1 LoSSI, which is part of LoSCAT, is a good clinical instrument to assess activity and severity in JLS lesions and is highly recommended in clinical practice.
- 2 LoSDI, which is part of LoSCAT, is a good clinical instrument to assess damage in JLS and is highly recommended in clinical practice.
- 3 Infrared thermography can be used to assess activity of the lesions in JLS, but skin atrophy can give false-positive results.
- 4 A specialised US imaging, using standardised assessment and colour Doppler, may be a useful tool for assessing disease activity, extent of JLS and response to treatment.
- 5 All patients with JLS at diagnosis and during follow-up should be carefully evaluated with a complete joint examination, including the temporomandibular joint.
- 6 MRI can be considered a useful tool to assess musculoskeletal involvement in JLS, especially when the lesion crosses the joint.
- 7 It is highly recommended that all patients with JLS involving face and head, with or without signs of neurological involvement, have an MRI of the head at the time of the diagnosis.
- 8 All patients with JLS involving face and head should undergo an orthodontic and maxillofacial evaluation at diagnosis and during follow-up.
- 9 Ophthalmological assessment, including screening for uveitis, is recommended at diagnosis for every patient with JLS, especially in those with skin lesions on the face and scalp.
- 10 Ophthalmological follow-up, including screening for uveitis, should be considered for every patient with JLS, especially in those with skin lesions on the face and scalp.



Investgations



Clinical assessment – specialist centre

Photos

Assessment scoring - LoSCAT

Examine joints +/- MRI

Consider skin biopsy and bloods

Consider imaging eg MRI head

Consider thermography


Consider ophthalmology review

Consider maxilofacial or orthodontic review

25% may have extra cutaneous associations...



Image from Dermnetnz.org



Arthritis





uveitis

Bloods

- Inflammatory markers if elevated can monitor response
- Muscle enzymes suggest muscle involvement
- Anti-nuclear antibodies (43-50%) may suggest extensive / severe disease
- Rheumatoid factor (15 25 %) extra-cutaneous features in LSc

(Wu 2019, Zulian 2006)

conference.edsuae.com

PATIENT IMAGES REMOVED






PATIENT IMAGES REMOVED

Affected foot - small, tight tendons. Affecting gait

Subcutaneous fat loss & joint contractures



Learning Objectives

Clinical features

Scoring tools

Management

Case examples

Psychosocial impact






- Aged 7
- Managed with super potent topical steroid
- Not increasing in size
- Inactive and symptomatic –topical tacrolimus

PATIENT IMAGES REMOVED

Aged 7

Aged 9

"The lesion is generally warmer than the contralateral area, the medial edge is the hottest area of the lesion. A small region drawn here measured 3.3 ° C warmer than the contralateral area . In the absence of any other explanation this does appear to indicate inflammation in this area"



ANNUAL CONFERENCE

- 6 years later
- Concern over erythema
- Thermography performed
- Considering MTX
- LoSDI 6

		oSDI ma Skin Damage Index	0
Dermal atrophy	Sub Q / Deep	Dyspigmentation	Skin Thickness (at
	atrophy	(hyper or hypo)	CENTER)
0 = none	0 = none	0 = none	0 = none
1 = shiny	1 = flat	1 = mild	1 = mild
2 = visible vessels	2 = concave	2 = moderate	2 = moderate
3 = cliff drop	3 = marked	3 = marked	3 = marked

PATIENT IMAGES REMOVED

En coup de sabre

3 yrs old

8-week history pale hairless patch no better with oral terbinafine

MRI head; Right frontal thinning of calvarium consistent with linear scleroderma no brain abnormality

MTX for 2 years stopped due to intolerance

Topical Sebco

PATIENT IMAGES REMOVED

18 months later



PATIENT IMAGES REMOVED

- LoSAI = 0 & LoSDI = 3 (06/22)
- LoSAI = 0 & LoSDI = 4 (09/23)
- LoSA1=0 today LosD1 = 4 today



Extending plaque

9 yrs old7-month historyNo response to topical antifungals

FH autoimmune disease Asthma Hyperhidrosis

PATIENT IMAGES REMOVED



PATIENT IMAGES REMOVED

Initial IV steroid - 3 months MTX 15 months (nausea and neutropenia) MMF from April 2024

LoSAI 15 - 0

LoSAI = 15; LoSDI = 9; PGA-A =80; PGA-D =70 (Dec 22)
LoSAI = 0 LoSDI = 12; PGA-A =80; PGA-D =70 (June 23)
LoSAI = 0 LoSDI = 13; PGA-A =0; PGA-D =70 (Sept 23)
LoSAI = 0 LoSDI = 13; PGA-A =0; PGA-D =70 (Dec 23)
LoSAI = 2 LoSDI = 13; PGA-A =0; PGA-D =70 (Mar 24)
LoSAI = 2 LoSDI = 10; PGA-A =0; PGA-D =50 (Jun 24)
LoSAI = 0 LoSDI = 9; PGA-A = 0; PGA-D =50 (today)

Bilateral changes



PATIENT IMAGES REMOVED

Referred aged 10 4-year history MRI x3 shows microhaemorrhages in brain parenchyma

Coexisting Alopecia areata

MTX for 2 years and initial IV steroid

3 months after stopping treatment - relapse Switched to MMF for 2 years



PATIENT IMAGES REMOVED

4 years later

No activity Minimal extension

Some new alopecia to scalp and eyelashes No relapse after stopping MMF

Extensive linear change

PATIENT IMAGES REMOVED

14 yr oldNoticed incidentallyPresent monthsKeen athlete

PATIENT IMAGES REMOVED

6 months later

20 months of MTX Initial 5 months of IV pred

Nausea with MTX

Great anxiety about relapse

LoSAI 21 - 0 LoSDI 20 - 3

- September 2022: LoSAI 21 and LoSDI 20. PGA-A 80/100; PGA-D 80/100 (at diagnosis)
- March 2023: LoSAI 0 and LoSDI 8. PGA-A 0/100; PGA-D 50/100
- June 2023: LoSAI 0 and LoSDI 11. PGA-A 0/100; PGA-D 50/100
- September 2023: LoSAI 0 and LoSDI 10. PGA-A 0/100; PGA-D 50/100
- December 2023: LoSAI 0 and LoSDI 10. PGA-A 0/100; PGA-D 40/100
- March 2024: LoSAI 0 and LoSDI 8. PGA-A 0/100; PGA-D 30/100
- June 2024: LoSAI 0 and LoSDI 8. PGA-A 0/100; PGA-D 20/100
- Today: LoSAI 0 and LoSDI 3. PGA-A 0/100; PGA-D 20/100

Extensive en coup de sabre

Seen aged 3 with 6 week history of increasing macule on forehead History of congenital nystagmus

Urgent biopsy and ophthalmology review

Admitted within days for IV steroid

- Initial IV steroid 14 months
- MTX 18 months initially stopped due to LFT's (Skin still active)
- Switched to MMF + Tocilizumab for 2 years with IV pred / oral pred intermittently
- Methotrexate added back in to allow reduction in steroids
- Currently in remission



PATIENT IMAGES REMOVED



Skin biopsy scalp aged 3 – early linear scleroderma

MRI head; left frontal skull abnormality, with loss of scalp tissue and thinning of the underlying bone

Multiple foci calcification – progression on subsequent scans (neurology supported use of tocilizumab)

Fat transfers with plastic surgery Considering further surgery

Camouflage clinic Eyebrow tattooing Ophthalmology input Clinical psychology

PATIENT IMAGES REMOVED





Learning Objectives

Clinical features

Scoring tools

Management

Case examples

Psychosocial impact

Psychosocial Impact

Factors

- Self-image
- Bullying
- Fear and anxiety progression / recurrence
- Burden of treatment needles, blood tests, medication

Nome:

Hospítal:

Doctors are

will be able t This question opposite the

Don't take to thought-out

eel lense ! Most

Allot

Visits – school attendance

Tools

- Health psychology
- Scores GAD, CDLQI, PHQ
- Art therapy
- Camouflage make up clinic
- MDT team input



PHQ-9 modified for Adolescents (PHQ-A)



Name:	Clinician:	Date	:			
	ave you been bothered by each of t a put an " X " in the box beneath the					
Ĭ		(0) (1) Not at Several all days	(2) More than	(3) Nearly every		
 Feeling down, depresse Little interest or pleasur 		CHILDRE	EN'S DERM	ATOLOGY LIFE	QUALITY INDEX	
 Trouble falling asleep, s much? Poor appetite, weight to 	Age: Age: Address:	Dat	Diagnosis te:	5:	CDLQI SCORE:	
 Feeling tired, or having Feeling bad about yours 	self – or feeling 1 The aim of th	is questionnaire is to ma OVER THE LAST WEE				
		the last week, how itchy or painful has your skin 1			Very much Quite a lot Only a little Not at all	
	2. Over	the last week, how emba			Very much	
Hospital Anxiety an	or se been	If conscious, upset or sad because of your skin?	l have you		Quite a lot Only a little Not at all	0
Hospital Anxiety an	or se been d Depression (HAD)	because of your skin? Scale Trial No:			Only a little	
emotions play an important par	d Depression (HAD)	because of your skin? Scale Trial No:		n Trust	Only a little	
	d Depression (HAD) Date of Complete t in most Illne:	because of your skin? Scale Trial No:		n Trust	Only a little	
emotions play an important par more, igned to help your doctor to kno	d Depression (HAD) Date of Complete t in most Illne:	because of your skin? Scale Trial No:		n Trust	Only a little	
emotions play an important par more, igned to help your doctor to kno h comes closest to how you har	d Depression (HAD) Date of Complete timest line: Whow you feeling action to eace	because of your skin? Scale Trial No:		n Trust	Only a little	
emotions play an important par more, igned to help your doctor to kno h comes closest to how you har your replies; your immediate re	d Depression (HAD) Date of Complete timest line: Whow you feeling action to eace	because of your skin? Scale Trial No:	S Foundatio	n Trust	Only a little	
emotions play an important par more. igned to help your doctor to kno h comes closest to how you har your replies: your immediate re <i>Tick only one</i> ip':	d Depression (HAD) Date of Complete Date	because of your skin? Scale Trial No:	S Foundatio	n Trust	Only a little	

Children and young people's health psychology - Newcastle Hospitals NHS Foundation Trust





- 1. De Silva U, Parish LC. Historical approach to scleroderma. Clin Dermatol. 1994;12:201–5
- 2. Dańczak-Pazdrowska A, Cieplewicz P, Żaba R, Adamski Z, Polańska A. Controversy around the morphea. Postepy Dermatol Alergol. 2021 Oct;38(5):716-720. doi: 10.5114/ada.2021.106242. Epub 2021 May 18. PMID: 34849114; PMCID: PMC8610066.
- 3. // Asano, Y., Fujimoto, M., Ishikawa, O., Sato, S., Jinnin, M., Takehara, K., Hasegawa, M., Yamamoto, T. and Ihn, H. (2018), Diagnostic criteria, severity classification and guidelines of localized scleroderma. *J Dermatol*, 45: 755-780.
- 4. Weibel L, Harper JI. Linear morphoea follows Blaschko's lines. Br J Dermatol. 2008 Jul;159(1):175-81. doi: 10.1111/j.1365-2133.2008.08647.x. Epub 2008 Jul 1. PMID: 18503590.
- 5. N.M. Teske, H.T. Jacobe, Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change, *British Journal of Dermatology*, Volume 182, Issue 2, 1 February 2020, Pages 398–404
- 6. Zulian F, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Annals of the Rheumatic Diseases 2019;78:1019-1024.
- 7. Wu et al. Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. ARC Open Rheumatology. Vol. 1, No. 2, April 2019, pp 119–124
- 8. Zulian et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology 2006; 45: 614-620
- 9. https://www.sruk.co.uk/
- 10. https://www.changingfaces.org.uk



8th YEAR 08-10 November 2024

InterContinental Dubai - Festival City United Arab Emirates



Morphoea in children, experience from a joint dermatology rheumatology clinic

Dr Charlotte Goodhead

